Primary immunodeficiency in the 9-year child
Zuleykha A. Aliskandieva,
Alaudin M. Aliskandiev,
Rakhmat M. Idrisova,
Magomed I. Izrailov,
Kistaman М. Amirova https://doi.org/10.46563/1560-9561-2023-26-6-455-458
EDN: oqipgt
Abstract
Primary immunodeficiency conditions are a heterogeneous group of disorders caused by defects in various parts of the immune system, manifested in the form of recurrent infectious and autoimmune diseases of varying severity. The authors describe own clinical observation to determine the principles of diagnosis and treatment of primary immunodeficiency in children in modern conditions. The average age of diagnosis of an immunodeficiency condition has been established to be best over 30 days, but often this time increases to several years. The data of the enrolment of primary immunodeficiency states of the Republic of Dagestan on the diagnosis and permanent replacement therapy of immunodeficiency states is also presented.
Acknowledgment. The study had no sponsorship.
Conflict of interest. The authors declare no conflict of interest.
Contribution:
Aliskandieva Z.A. — concept and design of the study, statistical processing of the material;
Idrisova R.M., Amirova K.M. — collection and processing of material;
Aliskandieva Z.A. — writing the text;
Aliskandiev A.M., Israilov M.I. — editing the text.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.
Received: October 16, 2023
Accepted: November 28, 2023
Published: December 27, 2023
About the Authors
Zuleykha A. Aliskandieva
Dagestan State Medical University
Russian Federation
Russian Federation
MD, PhD, Associate Prof. of the Department of Faculty and Hospital Pediatrics, Pediatrics of the FPC and Teaching Staff of the Dagestan State Medical University, Dagestan State Medical University, Makhachkala, 367000, Russian Federation
e-mail: aliskandieva@mail.ru
Alaudin M. Aliskandiev
Dagestan State Medical University
Russian Federation
Russian Federation
Rakhmat M. Idrisova
Dagestan State Medical University
Russian Federation
Russian Federation
Magomed I. Izrailov
Dagestan State Medical University
Russian Federation
Russian Federation
Kistaman М. Amirova
Dagestan State Medical University
Russian Federation
Russian Federation
References
1. Marciano B.E., Holland S.M. Primary immunodeficiency diseases: current and emerging therapeutics. Front. Immunol. 2017; 8: 937. https://doi.org/10.3389/fimmu.2017.00937
2. Yu J.E., Orange J.S., Demirdag Y.Y. New primary immunodeficiency diseases: context and future. Curr. Opin. Pediatr. 2018; 30(6): 806–20. https://doi.org/10.1097/MOP.0000000000000699
3. Műzes G., Sipos F. Primary immunodeficiency and autoimmune diseases. Orv. Hetil. 2018; 159(23): 908–18. https://doi.org/10.1556/650.2018.31064
4. Amaya-Uribe L., Rojas M., Azizi G., Anaya J.M., Gershwin M.E. Primary immunodeficiency and autoimmunity: A comprehensive review. J. Autoimmun. 2019; 99: 52–72. https://doi.org/10.1016/j.jaut.2019.01.011
5. Spoor J., Farajifard H., Rezaei N. Congenital neutropenia and primary immunodeficiency diseases. Crit. Rev. Oncol. Hematol. 2019; 133: 149–62. https://doi.org/10.1016/j.critrevonc.2018.10.003
6. Ballow M., Sánchez-Ramón S., Walter J.E. Secondary immune deficiency and primary immune deficiency crossovers: hematological malignancies and autoimmune diseases. Front. Immunol. 2022; 13: 928062. https://doi.org/10.3389/fimmu.2022.928062
7. Deenick E.K., Lau A., Bier J., Kane A. Molecular and cellular mechanisms underlying defective antibody responses. Immunol. Cell Biol. 2020; 98(6): 467–79. https://doi.org/10.1111/imcb.12345
8. Anderson J.T., Cowan J., Condino-Neto A., Levy D., Prusty S. Health-related quality of life in primary immunodeficiencies: Impact of delayed diagnosis and treatment burden. Clin. Immunol. 2022; 236: 108931. https://doi.org/10.1016/j.clim.2022.108931
9. Ziegler J.B., Ballow M. Primary immunodeficiency: new approaches in genetic diagnosis, and constructing targeted therapies. J. Allergy Clin. Immunol. Pract. 2019; 7(3): 839–41. https://doi.org/10.1016/j.jaip.2018.12.019
10. Dvorak C.C., Haddad E., Heimall J., Dunn E., Buckley R.H., Kohn D.B., et al. The diagnosis of severecombined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions. J. Allergy Clin. Immunol. 2023; 151(2): 539–46. https://doi.org/10.1016/j.jaci.2022.10.022
11. Taki M., Miah T., Secord E. Newborn Screening for Severe Combined Immunodeficiency. Immunol. Allergy Clin. North Am. 2021; 41(4): 543–53. https://doi.org/10.1016/j.iac.2021.07.007
12. Michniacki T.F., Seth D., Secord E. Severe combined immunodeficiency: a review for neonatal clinicians. Neoreviews. 2019; 20(6): e326–35. https://doi.org/10.1542/neo.20-6-e326
13. Sharma M., Dhaliwal M., Tyagi R., Goyal T., Sharma S., Rawat A. Microbiome and its dysbiosis in inborn errors of immunity. Pathogens. 2023; 12(4): 518. https://doi.org/10.3390/pathogens12040518
14. Leiding J.W., Ballow M. Precision medicine in the treatment of primary immunodeficiency diseases. Curr. Opin. Allergy Clin. Immunol. 2018; 18(2): 159–66. https://doi.org/10.1097/ACI.0000000000000431
15. Dilley M., Wangberg H., Noone J., Geng B. Primary immunodeficiency diseases treated with immunoglobulin and associated comorbidities. Allergy Asthma Proc. 2021; 42(1): 78–86. https://doi.org/10.2500/aap.2021.42.200113
16. Castagnoli R., Delmonte O.M., Calzoni E., Notarangelo L.D. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front. Pediatr. 2019; 7: 295. https://doi.org/10.3389/fped.2019.00295
17. Booth C., Romano R., Roncarolo M.G., Thrasher A.J. Gene therapy for primary immunodeficiency. Hum. Mol. Genet. 2019; 28(R1): R15–23. https://doi.org/10.1093/hmg/ddz170
18. Forlanini F., Chan A., Dara J., Dvorak C.C., Cowan M.J., Puck J.M., et al. Impact of genetic diagnosis on the outcome of hematopoietic stem cell transplant in primary immunodeficiency disorders. J. Clin. Immunol. 2023; 43(3): 636–46. https://doi.org/10.1007/s10875-022-01403-5
19. Puck J.M. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol. Rev. 2019; 287(1): 241–52. https://doi.org/10.1111/imr.12729
20. Blom M., Bredius R.G.M., van der Burg M. Future perspectives of newborn screening for inborn errors of immunity. Int. J. Neonatal. Screen. 2021; 7(4): 74. https://doi.org/10.3390/ijns7040074
21. Korsunskiy I., Blyuss O., Gordukova M., Davydova N., Zaikin A., Zinovieva N., et al. Expanding TREC and KREC utility in primary immunodeficiency diseases diagnosis. Front. Immunol. 2020; 11: 320. https://doi.org/10.3389/fimmu.2020.00320
22. Şentürk G., Ng Y.Y., Eltan S.B., Başer D., Ogulur I., Altındirek D., et al. Determining T and B cell development by TREC/KREC analysis in primary immunodeficiency patients and healthy controls. Scand. J. Immunol. 2022; 95(3): e13130. https://doi.org/10.1111/sji.13130
23. Boyarchuk O., Yarema N., Kravets V., Shulhai O., Shymanska I., Chornomydz I., et al. Newborn screening for severe combined immunodeficiency: The results of the first pilot TREC and KREC study in Ukraine with involving of 10,350 neonates. Front. Immunol. 2022; 13: 999664. https://doi.org/10.3389/fimmu.2022.999664
24. Veillette A., Zhang S., Shi X., Dong Z., Davidson D., Zhong M.C. SAP expression in T cells, not in B cells, is required for humoral immunity. Proc. Natl Acad. Sci. USA. 2008; 105(4): 1273–8. https://doi.org/10.1073/pnas.0710698105
25. Ruiz-Pablos M. CD4+ Cytotoxic T cells involved in the development of EBV-associated diseases. Pathogens. 2022; 11(8): 831. https://doi.org/10.3390/pathogens11080831
26. Mudde A.C.A., Booth C., Marsh R.A. Evolution of our understanding of XIAP deficiency. Front. Pediatr. 2021; 9: 660520. https://doi.org/10.3389/fped.2021.660520
27. López-Nevado M., González-Granado L.I., Ruiz-García R., Pleguezuelo D., Cabrera-Marante O., Salmón N., et al. Primary immune regulatory disorders with an autoimmune lymphoproliferative syndrome-like phenotype: immunologic evaluation, early diagnosis and management. Front. Immunol. 2021; 12: 671755. https://doi.org/10.3389/fimmu.2021.671755
28. De Ranieri D., Fenny N.S. Intravenous immunoglobulin in the treatment of primary immunodeficiency diseases. Pediatr. Ann. 2017; 46(1): 8–12. https://doi.org/10.3928/19382359-20161213-03
Review
For citations:
Aliskandieva Z.A., Aliskandiev A.M., Idrisova R.M., Izrailov M.I., Amirova K.М. Primary immunodeficiency in the 9-year child. Russian Pediatric Journal. 2023;26(6):455-458. (In Russ.) https://doi.org/10.46563/1560-9561-2023-26-6-455-458. EDN: oqipgt
Views:
119
Email this article 